financetom
Business
financetom
/
Business
/
T. Rowe Price June Assets Under Management Rise Month Over Month
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
T. Rowe Price June Assets Under Management Rise Month Over Month
Jul 11, 2025 6:54 AM

09:16 AM EDT, 07/11/2025 (MT Newswires) -- T. Rowe Price Group ( TROW ) reported preliminary assets under management Friday of $1.677 trillion as of June 30, up from $1.624 trillion in the previous month.

The company said its equity assets rose to $839 billion at the end of June from $806 billion as of May 31, and multi-assets increased to $583 billion from $566 billion.

Fixed-income assets, including money market, rose to $200 billion from $199 billion, while alternative assets climbed $55 billion from $53 billion, the investment management firm said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chipotle (CMG) Stock Edges Higher Thursday After Fresh 52-Week Lows
Chipotle (CMG) Stock Edges Higher Thursday After Fresh 52-Week Lows
Nov 13, 2025
Chipotle Mexican Grill ( CMG ) shares are trading marginally higher Thursday morning, attempting to stabilize after a marked decline that saw the stock hit new 52-week lows earlier this week. The fast-casual giant has struggled significantly in 2025, with shares now down approximately 47% year-to-date. CMG stock is gaining positive traction. See what is driving the move here. What...
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
Nov 13, 2025
Day One Biopharmaceuticals ( DAWN ) on Thursday agreed to acquire Mersana Therapeutics Inc. ( MRSN ) , a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers. DAWN is among today’s weakest performers. Get the scoop here The deal value comprises an upfront consideration of $25.00 per share in cash plus up to an aggregate...
Gartner Launches Senior Notes Offering
Gartner Launches Senior Notes Offering
Nov 13, 2025
10:43 AM EST, 11/13/2025 (MT Newswires) -- Gartner ( IT ) said Thursday it has commenced a registered public offering of senior unsecured notes under a shelf registration statement. The company said it plans to use net proceeds to repay borrowings under its existing revolving credit facility, cover related fees and expenses, and for general corporate purposes. Gartner ( IT...
Gilead Sciences Says Bictegravir, Lenacapavir Single-Tablet Regimen Meets Goal in Phase 3 HIV Trial
Gilead Sciences Says Bictegravir, Lenacapavir Single-Tablet Regimen Meets Goal in Phase 3 HIV Trial
Nov 13, 2025
10:17 AM EST, 11/13/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Thursday that a phase 3 trial of a single-tablet regimen of bictegravir and lenacapavir in adults with HIV met its primary endpoint of non-inferiority to multi-tablet regimens. The company said the primary endpoint was the proportion of patients with a viral load of at least 50 copies/mL...
Copyright 2023-2026 - www.financetom.com All Rights Reserved